Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Those who suffer myasthenia gravis experience muscle weakness that can affect the muscles we use to blink, smile and move our bodies. Researchers used a cutting-edge imaging technique to uncover new ...

Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...